Abstract | RATIONALE: The full D1 receptor agonist dihydrexidine (DHX) [(+/-)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride] is under clinical development (DAR-100) for Parkinson's disease and schizophrenia. Despite the clinical development of DHX, very little is known about its discriminative stimulus properties in rats. To more fully characterize the discriminative stimulus properties of DHX, we trained rats to discriminate DHX (3 mg/kg, i.p.) from vehicle. METHODS: Substitution tests in rats discriminating DHX (3 mg/kg, i.p.) from vehicle were performed with structurally distinct D1 receptor agonists with both partial and full intrinsic efficacy. In addition, the peripherally restricted D1 agonist, fenoldopam, was evaluated. RESULTS: CONCLUSIONS: DHX produces prominent dopamine D1 receptor agonist effects in vivo and is likely to produce subjective effects in humans similar to other D1 receptor agonists.
|
Authors | Scott D Gleason, Jeffrey M Witkin |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 186
Issue 1
Pg. 25-31
(May 2006)
ISSN: 0033-3158 [Print] Germany |
PMID | 16575553
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Dopamine Agonists
- Phenanthridines
- Receptors, Dopamine D1
- dihydrexidine
|
Topics |
- Animals
- Discrimination Learning
(drug effects)
- Dopamine Agonists
(pharmacology)
- Male
- Phenanthridines
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Receptors, Dopamine D1
(agonists)
|